Off-label Use of Anti-cancer Drugs in Norway -a Prospective Cohort Study

Launched by OSLO UNIVERSITY HOSPITAL · Jun 30, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of anti-cancer drugs that are being prescribed for purposes other than what they were originally approved for, a practice known as "off-label" use. The goal is to understand how effective these off-label treatments are in real-life situations, looking at how well they work for patients, how long they help control the cancer, and what side effects patients experience. Researchers will also gather information to better understand the cost of these treatments and how common their use is in Norway.

To participate in this study, you need to be at least 18 years old, have a confirmed cancer diagnosis, and be receiving an off-label anti-cancer drug. There are no specific exclusions, so if you meet these criteria, you could be eligible. If you join the study, you can expect to share your experiences with the treatment, including any side effects, and help contribute to valuable research that could improve future cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Verified cancer diagnosis (based on radiological, histological/cytological or operative evidence).
• • Treatment with off-label anti-cancer drug.
• • Age ≥ 18 years
• • Able to provide written informed consent.
• Exclusion Criteria:
• • None